Unknown

Dataset Information

0

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.


ABSTRACT:

Background

Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules in tumors are responsible for cetuximab therapy refractoriness. The role of programmed death ligand 2 (PD-L2), a ligand of PD-1, in the immune function is unclear. Here, we examined the regulatory mechanism of PD-L2 glycosylation and its role in antitumor immunity and cetuximab therapy.

Methods

Single-cell RNA sequencing and immunohistochemical staining were used to investigate PD-L2 expression in cetuximab-resistant/sensitive HNSCC tissues. The mechanism of PD-L2 glycosylation regulation was explored in vitro. The effects of PD-L2 glycosylation on immune evasion and cetuximab efficacy were verified in vitro and using mice bearing orthotopic SCC7 tumors.

Results

The PD-L2 levels were elevated and N-glycosylated in patients with cetuximab-resistant HNSCC. Glycosylated PD-L2 formed a complex with EGFR, which resulted in the activation of EGFR/signal transducer and activator of transcription 3 (STAT3) signaling and decreased the cetuximab binding affinity to EGFR. The N-glycosyltransferase fucosyltransferase (FUT8), a transcriptional target of STAT3, was required for PD-L2 glycosylation. Moreover, glycosylation modification stabilized PD-L2 by blocking ubiquitin-dependent lysosomal degradation, which consequently promoted its binding to PD-1 and immune evasion. Inhibition of PD-L2 glycosylation using Stattic, a specific STAT3 inhibitor, or PD-L2 mutation blocking its binding to FUT8, increased cytotoxic T lymphocyte activity and augmented response to cetuximab.

Conclusions

Increased expression and glycosylation of PD-L2 in tumors are an important mechanism for cetuximab therapy refractoriness. Thus, the combination of PD-L2 glycosylation inhibition and cetuximab is a potential therapeutic strategy for cancer.

SUBMITTER: Xu Y 

PROVIDER: S-EPMC8547513 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.

Xu Yiqi Y   Gao Zhenyue Z   Hu Ruxin R   Wang Yuqing Y   Wang Yuhong Y   Su Zheng Z   Zhang Xiaoyue X   Yang Jingxuan J   Mei Mei M   Ren Yu Y   Li Min M   Zhou Xuan X  

Journal for immunotherapy of cancer 20211001 10


<h4>Background</h4>Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules in tumors are responsible for cetuximab therapy refractoriness. The role of programmed death ligand 2 (PD-L2), a ligand of PD-1, in the immune function is unclear. Here, we examined the regulatory mechanism of PD-L2 glycosylati  ...[more]

Similar Datasets

| S-EPMC6287426 | biostudies-other
| S-EPMC6793936 | biostudies-literature
| S-EPMC11806061 | biostudies-literature
| S-EPMC11561227 | biostudies-literature
| S-EPMC10107526 | biostudies-literature
| S-EPMC10562488 | biostudies-literature
| S-EPMC11610131 | biostudies-literature
| S-EPMC10589324 | biostudies-literature
| S-EPMC8526383 | biostudies-literature